Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 12/20 | 0.43 |
| ▸ | THRA | P10827 | 8/20 | 0.43 |
| ▸ | RORC | P51449 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5278265 | 0.92 | THRB (0.46) | THRBTHRARORCKDM4EALDH1A1 | |
| SCHEMBL5277815 | 0.89 | THRB (0.44) | THRBTHRARORC | |
| SCHEMBL5286206 | 0.88 | THRB (0.43) | THRBTHRARORC | |
| SCHEMBL5278329 | 0.84 | THRB (0.41) | THRBTHRARORCALDH1A1TPMT | |
| SCHEMBL5284086 | 0.82 | THRB (0.59) | THRBTHRARORC | |
| SCHEMBL5279505 | 0.82 | THRA (0.49) | THRBTHRA | |
| SCHEMBL4351857 | 0.80 | THRA (0.69) | THRBTHRA | |
| SCHEMBL5278082 | 0.78 | THRB (0.44) | THRBTHRARORC | |
| SCHEMBL5280396 | 0.76 | KDM4E (0.46) | THRBTHRARORCKDM4EALDH1A1 | |
| SCHEMBL5279176 | 0.76 | NR3C1 (0.41) | THRBTHRARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1862450-A2 | Novel compounds | KARO BIO AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1537073-B1 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KAROBIO AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-7153997-B2 | Benzamide derivatives as thyroid receptor ligands | KARO BIO AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060135614-A1 | Novel compounds | NORIN, THOMAS ANDERS WILSON (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1537073-A2 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004007430-A2 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135614-A1 | Novel compounds | THRB, TSHR, THRA | THRB 1/4885THRA 3/4885RORC 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.